Search results
Results From The WOW.Com Content Network
Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [ 2 ] [ 6 ] [ 5 ] [ 4 ] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor ...
Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).
On Friday, Johnson & Johnson's Zytiga received an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer ...
Prednisone: 3.5–5 0.8 16–36 Prednisolone: 4 0.8 16–36 Methylprednisolone: 5–7.5 0.5 18–40 Dexamethasone: 25–80 0 36–54 Betamethasone: 25–30 0 36–54 Triamcinolone: 5 0 12–36 Deflazacort: 6.5 – 1.3 Fludrocortisone acetate: 15 200 24 Deoxycorticosterone acetate: 0 20 – Aldosterone: 0.3 200–1000 – Beclometasone
The neuropsychiatric effects are partly mediated by sensitization of the body to the actions of adrenaline. Therapeutically, the bulk of corticosteroid dose is given in the morning to mimic the body's diurnal rhythm; if given at night, the feeling of being energized will interfere with sleep. An extensive review is provided by Flores and Gumina ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer.
Prednisone is a glucocorticoid medication mostly used to suppress the immune system and decrease inflammation in conditions such as asthma, COPD, and rheumatologic diseases. [3] It is also used to treat high blood calcium due to cancer and adrenal insufficiency along with other steroids . [ 3 ]
[132] [31] [133] [127] This may be why they have greater efficacy than steroidal AR antagonists in the treatment of prostate cancer and is an important reason as to why they have largely replaced them for this indication in medicine. [132] [31] [133] [127] Nonsteroidal antiandrogens have relatively low affinity for the AR compared to steroidal ...